Search Results

Mortality After TAVI in Patients With Severe Aortic Stenosis Studied

January 18, 2011—According to Corrado Tamburino, MD, et al, there is a lack of information on the incidence and predictors of early mortality at 30 days and late mortality between 30 days and 1 year after transcatheter aortic valve implantation (TAVI) with the self-expanding CoreValve Revalving prosthesis (Medtronic, Inc., Minneapolis, MN).

Italian OBSERVANT Study Compares 1-Year Outcomes for TAVR and Surgery

August 17, 2015—Corrado Tamburino, MD, et al published results from the Italian OBSERVANT study in the Journal of the American College of Cardiology  (JACC; 2015;66:804–812).

TAVI Compares Favorably to Surgery in Italian Registry

February 23, 2012—One-year data comparing complications and outcomes of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) were published by Corrado Tamburino, MD, et al online ahead of print in the American Journal of Cardiology.

Evalve Initiates Postmarket Study of MitraClip

April 6, 2009—Evalve, Inc. (Menlo Park, CA) announced the commencement of enrollment in the ACCESS-Europe postmarket observational study of the company's MitraClip therapy in Europe.

Boston Scientific Launches Taxus Element DES in Europe

June 10, 2010—Boston Scientific Corporation (Natick, MA) announced the market launch of its Taxus Element paclitaxel-eluting coronary stent system in the European Union and other CE Mark countries.

Stentys Completes APPOSITION II Enrollment

July 15, 2010—Stentys, Inc. (Princeton, NJ) announced the completion of patient enrollment in the APPOSITION II clinical study, a randomized trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in patients with acute myocardial infarction (AMI).

Symetis Acurate Neo TAVR Device Fails to Show Noninferiority in SCOPE II Trial

October 15, 2020—In the randomized SCOPE II clinical trial, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate noninferiority compared to an existing self-expanding valve.